Evaluation of the Bioequivalence of the 20 mg /10 ml Doses of Two Injectable Preparations of Eptifibatide: A Randomized, Open-Label, Two-Period Crossover Study in Healthy Adult Male Chinese Volunteers

摘要

@@ Eptifibatide is a small, synthetic, cyclic heptapeptide, containing six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. Chemically it is N6-(aminoiminomethyl)-N2-(3-mercapto-1 -oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic disulfide). It inhibits platelet function in a dose-specific fashion by reversibly binding the platelet GP Hb/Ⅲa receptor,[1] which is the aim target for the treatment of patients with coronary syndrome[1,2].